ESPE Abstracts (2019) 92 P2-198

Evaluation of Diagnosis, Follow-up and Treatment Results of Growth Hormone in Rare Diseases; 10 Year Single Center Experience

Zehra Aycan1, Aslıhan Araslı Yilmaz2, Şervet Yel2, Senay Savas Erdeve2, Semra Çetinkaya2

1Ankara University Medicine Faculty, Pediatric Endocrinology Department, Ankara, Turkey. 2Dr.Sami Ulus Maternity, Child Health and Diseases Training and Research Hospital, Pediatric Endocrinology Department,, Ankara, Turkey

Introduction: Growth hormone therapy (GHT); have been used in rare diseases such as growth hormone deficiency (GHD), panhipopituitarism (PHP), intrauterine growth retardation (IUGR), Turner Syndrome(TS) for many years while the effects of diagnostic timing on the treatment results are known. However,data on the diagnosis and treatment processes of these diseases are limited in our country. The aim of this study was to evaluate the results of diagnosis, follow-up and treatment of the patients who were started GHT for the last 10 years and to determine the differences in the process and results over the years.

Materials and Methods: 857 patients who underwentGHT between 2009-2018 were evaluated retrospectively in all patients and subgroups(GHD, PHP, IUGR, TS) in terms of GHT onset time, follow-up, GHT offset time, anthropometric, clinical, laboratory data, treatment adherence and side effects.

Results: GHT was started in 695 cases (81.1%) with GHD, 24 (2.8%) with PHP, 26 (3%) with IUGR and 28 (3.3%) with TS. The median age of onset of GHT was 12.2 years and the earliest was on IUGR (8.6 years) on the other hand, it was at the latest on GHD (12.3 years). In 17% of patients, treatment was interrupted due to adjustment problem, low growth rate and IGF1 increase.Side effects were seen in 3% of the patients (significant elevated CK, scoliosis, cardiac causes). At the time of treatment offset, height SDS in GHD and PHP were significantly higher than treatment onset time, whereas there was no significant difference in TS and IUGR. 218 cases reached the final height. Final lengths in boys/girls were respectively in GHD:153/164,1cm PHP:155,6/162,7cm; TS:147,2cm(133-156.4); IUGR:144.6 (136.7- 150.3), respectively. Of the 166 GHD patients who reached their final height,104 (67.5%) were found to reach their target height.

Conclusion: In this study, 81.1% of 857 patients who had undergone GHT were treated with the diagnosis of GHD, no difference was observed in the last 10 years between the age of presentation and treatment of the patients and the treatment was started late. The patients' compliance with treatment was high (91%) and the incidence of side effects was low(3%). Approximately 68% of 166 GHD cases reached the target height. Considering the findings of our study, it was concluded that due to short stature in our country, age at admission and onset of GHT were late and there is a need for more studies on this subject.

Article tools

My recent searches

No recent searches.